Research programme: eye disorder therapeutics - InSite Vision

Drug Profile

Research programme: eye disorder therapeutics - InSite Vision

Alternative Names: BromDex; Bromfenac/dexamethasone ophthalmic - InSite Vision; ISV-102; ISV-215; ISV-504

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator InSite Vision
  • Class Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Prostaglandins; Small molecules; Tetracyclines
  • Mechanism of Action Cyclooxygenase inhibitors; Glucocorticoid receptor agonists; Immunosuppressants; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Glaucoma; Ocular inflammation; Ocular pain; Ophthalmic infections

Most Recent Events

  • 28 Feb 2018 No recent reports of development identified for research development in Ocular-inflammation in USA (Ophthalmic, Drops)
  • 28 Feb 2018 No recent reports of development identified for research development in Ocular-pain in USA (Ophthalmic, Drops)
  • 16 Jul 2016 No recent reports of development identified for research development in Glaucoma in USA (Ophthalmic, Drops)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top